MTOR and cardiac hypertrophy: This conclusion is corroborated by the reversion of cardiac hypertrophy in MKK6-deficient mice also deficient for cardiac p38γ or p38δ, and further corroboration comes from the ability of the mTOR inhibitor rapamycin to prevent cardiac hypertrophy during early postnatal cardiac development in MKK6-deficient mice.